LOGIN
ID
PW
MemberShip
2025-02-07 03:33
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
"Confirmed long-term Tx effects of Camzyos¡¦new oHCM Tx"
by
Son, Hyung Min
Dec 13, 2024 05:51am
"In a clinical study spanning three years, Camzyos has demonstrated consistent patient symptom management and safety in many patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its proven efficacy in long-term treatment, it is expected that many patients with oHCM can significantly improve their quality of life through this t
Company
NeuroBiogen enters into Binding Term Sheet with US Company
by
Lee, Seok-Jun
Dec 12, 2024 05:50am
Scilex Holding Company, a Nasdaq-listed company, announced that d a binding Term Sheet&160;had been signed between NeuroBiogen, a Korean company specializing in innovative new drugs, and Scilex Bio, a controlling interest of joint venture by Scilex Holding Company on December 10th, local time. Under the terms of the agreement, Scilex Bio
Company
'Effective in Asian patients' Leclaza vs Tagrisso comb
by
Son, Hyung Min
Dec 12, 2024 05:49am
Leclaza plus Rybrevant and Tagrisso plus platinum-based chemotherapy have shown consistent effects in Asian patients. The effects of the combination therapy of Leclaza and Tagrisso, which are non-small cell lung cancer (NSCLC) treatments, have been unveiled at the European Society for Medical Oncology (ESMO) Asia Congress 2024. ESMO Asia Con
Company
Merck Biopharma Korea and LG Chem will comarket Glucophage
by
Whang, byung-woo
Dec 12, 2024 05:49am
Merck Biopharma Korea announced on the 11th that it has signed a partnership agreement with LG Chem to jointly sell Glucophage (metformin hydrochloride), a treatment for type 2 diabetes, in Korea.&160; Under the agreement, LG Chem will distribute Glucophage to healthcare providers in Korea starting January 1, 2025. Merck Biopharma Kore
Company
'Lalaola' wins 2024 Pharma Industry ad grand prize
by
Son, Hyung Min
Dec 11, 2024 05:54am
The winner of the 2024 pharmaceutical and biotechnology industry advertising¡¤PR awards has been announced. Yuhan's 'Lalaola' won the Grand Prize in the advertising category, and Amgen Korea's 'Blue Wish campaign' won the Grand Prize in the PR category. On December 10, Dailypharm (Publisher: Lee Jeong Seok) hosted the '2024 Korean Pharmaceut
Company
Lilly will directly distribute Trulicity in Korea next year
by
Lee, Tak-Sun
Dec 11, 2024 05:54am
Lilly, who holds the marketing authorization for the diabetes drug ¡®Trulicity (dulaglutide),¡¯ which has been distributed by Boryung since 2016, will directly distribute the drug in Korea from next year. With the launch of the diabetes and obesity drug Mounjaro (tirzepatide) expected next year, it is expected that this change of distrib
Company
Jemperli expands indication to all endometrial cancers
by
Whang, byung-woo
Dec 11, 2024 05:52am
Jemperli's (dostarlimab) indication was expanded to include its use as a first-line treatment in combination with platinum-based chemotherapy for all patients with advanced or recurrent endometrial cancer. The drug is expected to further expand its influence, with the Health Insurance Review and Assessment Service's Cancer Disease Deliberati
Company
MM drug Revlimid continues to thrive after patent expiry
by
Eo, Yun-Ho
Dec 11, 2024 05:52am
Sales of the multiple myeloma drug Revlimid continue to thrive even after patent expiry in Korea. According to industry sources, Bristol Myers Squibb Korea¡¯s Revlimid (lenalidomide) still boasts its originality with an 80% market share. As of Q3 2024 (IQVIA), Revelimid's sales were KRW 11.2 billion, significantly outpacing the sales
Company
Antibiotic clarithromycin market grows fourfold in 3 yrs
by
Chon, Seung-Hyun
Dec 10, 2024 05:53am
The prescription market for the antibiotic clarithromycin has significantly expanded. The market size grew by nearly fourfold over three years. Impurities-related cautions were once issued, but the volume of use increased during the COVID-19 pandemic and endemic period. According to a pharmaceutical market research firm UBIST on December 9, t
Company
1st MET-targeting anticancer drug likely to get reimb in KOR
by
Eo, Yun-Ho
Dec 10, 2024 05:53am
The MET-targeting anticancer drug 'Tepmetko' has passed the review process for reimbursement listing three years after being approved in South Korea.. Sources said that Merck Korea's Tepmetko (tepotinib), a treatment for patients with topically advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial tran
1
2
3
4
5
6
7
8
9
10
>